Clinical Trial Update: Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 study evaluating PRO 140 (leronlimab) as single-agent maintenance therapy in virally suppressed CCR5-tropic HIV-1 infection has completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• PRO 140 (leronlimab) (leronlimab)

Snippet

Sponsor: CytoDyn, Inc. | Conditions: HIV | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2026-03-04